With 18 clinical providers, Katzen Eye Group serves an active and varied patient population of 180,000, for indications that include cataract surgery, retina, glaucoma, refractive surgery, and dry eye, as well as routine eye and contact lens care.
"We have the ideal population to help advance eye care," explains Richard C. Edlow, DO, Katzen Eye Group's CEO. "Our electronic medical records system is optimized to enable us to identify and contact appropriate potential study subjects. We are very pleased to partner with RxTrials, who in our opinion, has the expertise and experience we need to do research right."
Katzen Eye Group is equipped to conduct clinical research studies, with
comprehensive testing and diagnostic capabilities and essential equipment in all three locations. Past research experience includes studies in macular edema, age-related macular degeneration, retinal detachment, and implants, among others. All 11 principal investigators are trained in clinical study practice, human subject protections, and federal compliance standards.
"As we look to grow our network of partner sites strategically, we seek sites that can adhere to our high standards for quality, professionalism and ethics," said Adam Chasse, RxTrials' vice president of corporate development. "Katzen Eye Group is a high quality addition to our network and enables us to enhance our therapeutic capabilities in ophthalmology and optometry."